Overview
Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
Status:
Completed
Completed
Trial end date:
2008-10-01
2008-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to investigate whether the prophylactic use of itraconazole is a better option than empirical use of itraconazole in the management (prevention and treatment) of fungal infection associated with high-dose chemotherapy and autologous hematopoietic stem cell transplantation in children with high-risk solid tumor.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Samsung Medical CenterTreatments:
Hydroxyitraconazole
Itraconazole
Criteria
Inclusion Criteria:- Patients with high risk solid tumors who are going to receive high dose chemotherapy
and autologous hematopoietic stem cell transplantation
Exclusion Criteria:
- Significant organ toxicity (National Cancer Institute [NCI] grade > 2) prior to high
dose chemotherapy and autologous hematopoietic stem cell transplantation